Reverso Therapeutics: Development and In Vivo Validation of Next-Generation Reversable Anticoagulants.

• Forschungsstelle: INNOSUISSE
• Projektnummer: 131.499 IP-LS
• Projekttitel Englisch: Reverso Therapeutics: Development and In Vivo Validation of Next-Generation Reversable Anticoagulants.

Schlüsselwörter (Englisch)

Life sciences, Pharmaceuticals

Abstract (Englisch)

Anticoagulants are life-saving drugs that prevent dangerous blood clots but carry a risk of bleeding. This project will de-risk the development of a new anticoagulant that can be instantly reversed with a simple antidote, making this therapy safer, especially for patients at high risk of bleeding.